01 Jul FarmaMondo appointed by Orion Pharma to Manage Access for levosimendan IV (Simdax®) for Swiss market
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Orion Pharma to distribute Simdax® via a Managed Access Program for targeted Healthcare Providers in Switzerland.
SIMDAX (levosimendan IV) is an inodilator (calcium sensitizer and potassium channel opener) indicated for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. SIMDAX is the only inodilator to provide long lasting hemodynamic benefits and symptom control to patients with acute heart failure and in need of inotropic therapy.
Program Contact details
For all inquiries regarding Simdax®, please
contact FarmaMondo Program Manager, Simdax®, Swiss Access. firstname.lastname@example.org, Phone: +41 91 6976392
FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
About Orion Pharma
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.